MediGene Receives One-Time Payment for License Agreement with Glaxo Group
MediGene AG has issued a non-exclusive license to Glaxo Group Limited under existing patents that had emerged from MediGene's program to develop a therapeutic tumor vaccine. In return MediGene receives a one-time payment from Glaxo Group Ltd.
The payment from Glaxo, combined with Eligard® sales, will ensure that Medigene will reach previous established guidance for 2005 of revenues of 20 million EUR. MediGene management is now postponing the finalization of the Polyphenon® E marketing partnership in order to review new proposals received after the recent FDA acceptance of the New Drug Application for Polyphenon® E-Ointment for the Treatment of Genital Warts.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.